Necrotizing Fasciitis Market Report 2026

Necrotizing Fasciitis Market Overview

• Necrotizing Fasciitis market size has reached to $1.17 billion in 2025 • Expected to grow to $1.82 billion in 2030 at a compound annual growth rate (CAGR) of 9.1% • Growth Driver: The Increasing Incidence Of Bacterial Infections Drives The Growth Of The Market Due To Rising Antibiotic Resistance • Market Trend: Innovative Therapies Transform Infection And Chronic Wound Care • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Necrotizing Fasciitis Market?

Necrotizing fasciitis is a rare but severe and rapidly progressive bacterial infection that causes extensive destruction of the skin, subcutaneous fat, and fascia, the connective tissue enveloping muscles. This life-threatening condition is typically caused by virulent bacteria such as Streptococcus pyogenes or Staphylococcus aureus and is often referred to as a flesh-eating disease. Prompt diagnosis and immediate medical intervention are critical to patient survival and typically involve broad-spectrum intravenous antibiotic therapy, aggressive surgical debridement, and, in severe cases, intensive supportive care to manage systemic complications such as sepsis and multiorgan failure. The main treatment types of necrotizing fasciitis are surgical debridement, antibiotic therapy, hyperbaric oxygen therapy, and other treatment types. Surgical debridement refers to the medical procedure of removing dead, infected, or damaged tissue from the body to stop the spread of the severe bacterial infection and promote healing. The disease is classified into types I, II, and III and affects various age groups, including pediatric, adult, and geriatric patients. Treatments are distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies. They are used by various end-users, including hospitals, specialized clinics, emergency care centers, home healthcare providers, and pharmaceutical companies.

What Is The Necrotizing Fasciitis Market Growth Forecast?

The necrotizing fasciitis market size is expected to see strong growth in the next few years. It will grow to $1.82 billion in 2030 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to development of targeted antimicrobial therapies, increasing adoption of precision diagnostics, expansion of advanced critical care infrastructure, growing research into immunomodulatory treatments, rising focus on rapid-response infection management protocols. Major trends in the forecast period include increasing focus on early diagnostic interventions, rising adoption of advanced antibiotic regimens, growing use of adjunctive therapies, expansion of multidisciplinary critical care approaches, enhanced emphasis on rapid surgical management.

Global Necrotizing Fasciitis Market Segmentation

1) By Treatment Type: Surgical Debridement, Antibiotic Therapy, Hyperbaric Oxygen Therapy, Other Treatment Types 2) By Type: Type I, Type II, Type III 3) By Age Group: Pediatric, Adult, Geriatric 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 5) By End-User: Hospitals, Specialized Clinics, Emergency Care Centers, Home Healthcare Providers, Pharmaceutical Companies Subsegments: 1) By Surgical Debridement: Early Debridement, Radical Debridement, Serial Debridement, Fasciotomy 2) By Antibiotic Therapy: Intravenous Antibiotics, Oral Antibiotics, Combination Therapy, Targeted Therapy 3) By Hyperbaric Oxygen Therapy: Monoplace Chamber Therapy, Multiplace Chamber Therapy, Adjunctive Therapy, Postoperative Therapy 4) By Other Treatment Types: Immunoglobulin Therapy, Supportive Care, Wound Care Management, Pain Management

What Are The Drivers Of The Necrotizing Fasciitis Market?

The increasing incidence of bacterial infections is expected to propel the growth of the necrotizing fasciitis market going forward. Bacterial infections refer to diseases or conditions caused by harmful bacteria invading and multiplying within the body, leading to tissue damage and illness. The increasing incidence of bacterial infections is primarily due to antibiotic resistance, which reduces the effectiveness of standard treatments and allows infections to persist and spread. The increasing incidence of bacterial infections creates a higher-risk environment for severe soft tissue infections, directly supporting the prevalence and aggressive progression of necrotizing fasciitis as opportunistic pathogens exploit weakened host defenses to rapidly invade fascial planes. For instance, in March 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, the number of tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, representing a rise of 1,295 cases. Therefore, the increasing incidence of bacterial infections is driving the growth of the necrotizing fasciitis industry. The rising healthcare expenditure is expected to propel the growth of the necrotizing fasciitis market going forward. Healthcare expenditure refers to the total amount of financial resources allocated by governments, private insurers, businesses, and individuals toward medical services, treatments, medications, and related health activities. Healthcare expenditure is increasing due to the growing prevalence of chronic diseases, which require long-term medical management and continuous therapeutic interventions. Healthcare expenditure enhances the management of necrotizing fasciitis by improving access to advanced diagnostics, innovative therapies, and specialized care. For instance, in June 2025, according to the Centers for Medicare & Medicaid Services, a US-based government agency, in 2023, national health expenditures (NHE) increased by 7.5% to reach $4.9 trillion, averaging $14,570 per person and representing 17.6% of the Gross Domestic Product (GDP). Medicare spending rose by 8.1% to $1,029.8 billion, accounting for 21% of total NHE. Therefore, rising healthcare expenditure is driving the growth of the necrotizing fasciitis industry.

Key Players In The Global Necrotizing Fasciitis Market

Major companies operating in the necrotizing fasciitis market are GlaxoSmithKline Public Limited Company, Gilead Sciences Inc., Teva Pharmaceutical Industries Limited, Merck And Co. Inc., bioMérieux S.A., Cipla Limited, Dr. Reddy’s Laboratories Limited, Hikma Pharmaceuticals PLC, Mankind Pharma Limited, Wockhardt Limited, Xellia Pharmaceuticals ApS, Basilea Pharmaceutica International Ltd., Avita Medical Inc., HiMedia Laboratories Pvt. Ltd., CutisCare Pvt. Ltd., NovaBay Pharmaceuticals Inc., TCS Biosciences Ltd., 3i Diagnostics Limited, Antabio S.A.P., Pfizer Inc.

Global Necrotizing Fasciitis Market Trends and Insights

Major companies operating in the necrotizing fasciitis market are focusing on developing innovative therapies, such as antibiotics and immunotherapies, to target biologics and novel wound care solutions. Antibiotics are medicines that kill or stop the growth of bacteria, while immunotherapies are treatments that boost or modify the body's immune system to fight infections or diseases. For instance, in March 2025, Altru Health System, a US-based nonprofit physician-led healthcare organization, launched Hyperbaric Oxygen Therapy (HBO) to enhance wound healing and support recovery in patients with chronic or hard-to-heal conditions. The therapy delivers 100% oxygen in a pressurized chamber, improving tissue oxygenation and promoting the body’s natural healing processes. It is aimed at treating conditions such as diabetic foot ulcers, radiation-induced tissue damage, compromised skin grafts, and severe infections, offering a non-invasive adjunct to conventional medical care.

Regional Outlook

North America was the largest region in the necrotizing fasciitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Necrotizing Fasciitis Market?

The necrotizing fasciitis market includes revenues earned by entities through diagnosis and laboratory testing services, surgical and debridement services, antibiotic and drug therapy management, wound care and infection control services, and research and development services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Necrotizing Fasciitis Market Report 2026?

The necrotizing fasciitis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the necrotizing fasciitis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.